[{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Eureka Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Series E Financing","leadProduct":"ET140202","moa":"Alpha-fetoprotein (AFP)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lyell Immunopharma","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Lyell Immunopharma","highestDevelopmentStatusID":"7","companyTruncated":"Lyell Immunopharma \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"LYL314","moa":"CD19\/CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lyell Immunopharma \/ Undisclosed"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19\/CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lyell Immunopharma \/ Undisclosed"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||NY-ESO-1","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lyell Immunopharma \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ GSK"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"LYL797","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Undisclosed"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"LYL797","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Undisclosed"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"LYL797","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Undisclosed"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"LYL797","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Undisclosed"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"ImmPACT Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Acquisition","leadProduct":"IMPT-314","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lyell Immunopharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Lyell Immunopharma","highestDevelopmentStatusID":"7","companyTruncated":"Lyell Immunopharma \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"ImmPACT Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Acquisition","leadProduct":"IMPT-314","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lyell Immunopharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Lyell Immunopharma","highestDevelopmentStatusID":"7","companyTruncated":"Lyell Immunopharma \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"IMPT-514","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lyell Immunopharma \/ Undisclosed"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"LYL845","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lyell Immunopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Undisclosed"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"LYL845","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lyell Immunopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Undisclosed"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"LYL845","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lyell Immunopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Undisclosed"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"LYL845","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lyell Immunopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Undisclosed"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Orca Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Lyell Immunopharma \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Sonoma Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Lyell Immunopharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Lyell Immunopharma \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Lyell Immunopharma \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Rondecabtagene Autoleucel","moa":"CD19\/CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lyell Immunopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyell Immunopharma \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Lyell Immunopharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
